ABSTRACT
Monte Carlo simulations using patient CT images as input are the gold standard to perform patient-specific dosimetry. However, in standard clinical practice patient's CT images are limited to the reconstructed CT scan range. In this study, organ dose calculations were performed with ImpactMC for chest and cardiac CT using whole-body and anatomy-specific voxel models to estimate the accuracy of CT organ doses based on the latter model. When the 3D patient model is limited to the CT scan range, CT organ doses from Monte Carlo simulations are the most accurate for organs entirely in the field of view. For these organs only the radiation dose related to scatter from the rest of the body is not incorporated. For organs lying partially outside the field of view organ doses are overestimated by not accounting for the non-irradiated tissue mass. This overestimation depends strongly on the amount of the organ volume located outside the field of view. To get a more accurate estimation of the radiation dose to these organs, the ICRP reference organ masses and densities could form a solution. Except for the breast, good agreement in dose was found for most organs. Voxel models generated from clinical CT examinations do not include the overscan in the z-direction. The availability of whole-body voxel models allowed to study this influence as well. As expected, overscan induces slightly higher organ doses.
ABSTRACT
BACKGROUND: While diagnostic reference levels (DRLs) are well-established for the radiopharmaceutical part, published DRLs for the CT component of positron emission tomography/computed tomography (PET/CT) and single photon emission computed tomography/computed tomography (SPECT/CT) are limited. This systematic review and meta-analysis provides an overview of the different objectives of CT in hybrid imaging and summarizes reported CT dose values for the most common PET/CT and SPECT/CT examinations. Also, an overview of already proposed national DRLs is given. METHODS: A systematic literature search was performed to identify original articles reporting CT dose index volume (CTDIvol), dose-length product (DLP) and/or national DRLs for the most frequently performed PET/CT and/or SPECT/CT examinations. Data were grouped according to the clinical objective: diagnostic (D-CT), anatomical localisation (AL-CT) or attenuation correction (AC-CT) CT. Random-effects meta-analyses were conducted. RESULTS: Twenty-seven articles were identified of which twelve reported national DRLs. For brain and tumour PET/CT imaging, CTDIvol and DLP values were higher for a D-CT (brain: 26.7 mGy, 483 mGy cm; tumour: 8.8 mGy, 697 mGy cm) than for an AC/AL-CT (brain: 11.3 mGy, 216 mGy cm; tumour: 4.3 mGy, 419 mGy cm). Similar conclusions were found for bone and parathyroid SPECT/CT studies: D-CT (bone: 6.5 mGy, 339 mGy cm; parathyroid: 15.1 mGy, 347 mGy cm) results in higher doses than AL-CT (bone: 3.8 mGy, 156 mGy cm; parathyroid: 4.9 mGy, 166 mGy cm). For cardiac (AC-CT), mIBG/octreotide, thyroid and post-thyroid ablation (AC/AL-CT) SPECT/CT pooled mean CTDIvol (DLP) values were 1.8 mGy (33 mGy cm), 4.6 mGy (208 mGy cm), 3.1 mGy (105 mGy cm) and 4.6 mGy (145 mGy cm), respectively. For all examinations, high variability in nuclear medicine practice was observed. CONCLUSION: The large variation in CT dose values and national DRLs highlights the need for optimisation in hybrid imaging and justifies the clinical implementation for nuclear medicine specific DRLs.